Focus will be on validating translational KineMarker technology in fibrosis.
KineMed and Roche will collaborate to jointly validate KineMed’s technology that helps transfer therapeutic agents into advanced clinical studies. KineMarker™ measures the on-mechanism activity of compounds in whole body systems in animals and man.
The companies will clinically validate the KineMarker of collagen synthesis, a therapeutic target underlying tissue fibrosis, in an undisclosed disease area.
“Fibrosis is a critical process underlying important diseases affecting major organ systems, including the lungs, kidneys, and liver,” points out David Fineman, president and CEO of KineMed. “The research collaboration with Roche will help to establish our approach as a possible surrogate for an important indication and as a means for monitoring on-mechanism activity of drug candidates in ensuing clinical studies.”